FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 86 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Is That New Lump or Bump a Sarcoma? February 28, 2023 Cancer in My Community: Advancements in Cancer Care in Singapore December 2, 2021 Reducing the Cancer Burden: Future Directions for NCI’s Cancer Control Research December 19, 2022 Conducting Phase I Clinical Trials During the COVID-19 Pandemic August 5, 2020 Load more HOT NEWS What People With Cancer and Survivors Should Know About Vaping: An... Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma Representation, retention and hope – how a mentorship scheme is helping...
